RSV is a common virus that primarily affects the respiratory tract. While it is most often associated with infections in infants and young children, adults can also contract RSV. Adults who are more susceptible to RSV usually have weakened immune systems, older adults, or those who have underlying health conditions.
Symptoms in adults are typically : cough, runny/stuffy nose, sore throat, fever, wheezing, and shortness of breath. However, if you have COPD or Asthma breathing conditions can become acute if not properly treated, which could lead to an exacerbation.
Patients with heart disease, cancer patients, organ transplant recipients, diabetes, or obesity can also lead to a more severe complications.
Prevention measures include practicing good hand hygiene, avoiding close contact with infected individuals, and cleaning surfaces regularly.
Currently there is no specific treatment for RSV in adults other than manage the symptoms with over the counter medications, hydrate and rest.
VACCINE DEVELOPMENT:
There have been several efforts to develop an effective RSV vaccine over the years. Recent developments have focused on more innovative techniques, including mRNA technology, which has gained prominence due to the success of COVID-19 vaccines.
Fortunately, NHRG has had the privilege to work with a couple of those companies in the past few years to help get those vaccines on the market. Once approved, widespread vaccination could play a crucial role in preventing RSV infections and their complications.